THERACHON
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.
THERACHON
Industry:
Biotechnology Medical Therapeutics
Founded:
2014-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.therachon.com
Total Employee:
11+
Status:
Closed
Contact:
+41798989209
Email Addresses:
[email protected]
Total Funding:
100 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Dyn DNS Dyn Hosting
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2018-10-09 | GLyPharma Therapeutic | GLyPharma Therapeutic acquired by Therachon | N/A |
Investors List
Pfizer Venture Investments
Pfizer Venture Investments investment in Series B - Therachon
Inserm Transfert Initiative
Inserm Transfert Initiative investment in Series B - Therachon
Bpifrance
Bpifrance investment in Series B - Therachon
Versant Ventures
Versant Ventures investment in Series B - Therachon
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series B - Therachon
OrbiMed
OrbiMed investment in Series B - Therachon
Tekla Capital Management
Tekla Capital Management investment in Series B - Therachon
Novo Holdings
Novo Holdings investment in Series B - Therachon
Inserm Transfert Initiative
Inserm Transfert Initiative investment in Series A - Therachon
OrbiMed
OrbiMed investment in Series A - Therachon
Official Site Inspections
http://www.therachon.com
- Host name: 147.154.27.36
- IP address: 147.154.27.36
- Location: Seattle United States
- Latitude: 47.6109
- Longitude: -122.3303
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98101
More informations about "Therachon"
Therachon - Crunchbase Company Profile & Funding
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, …See details»
Therachon
TherachonSee details»
Pfizer Completes Acquisition of Therachon
Jul 1, 2019 Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. …See details»
Therachon Company Profile 2024: Valuation, Funding & Investors
Therachon General Information Description. Developer of novel therapeutics intended to facilitate treatment for rare genetic diseases. The company develops pipeline of therapeutics focused …See details»
Pfizer acquires Therachon - 2019-05-08 - Crunchbase
May 8, 2019 Acquired Organization: Therachon Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases. Acquiring Organization: Pfizer …See details»
Therachon - Funding, Financials, Valuation & Investors - Crunchbase
Sep 30, 2020 Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. …See details»
Pfizer to purchase biotech firm Therachon for up to $810m
Pfizer has agreed to acquire Swiss biotechnology firm Therachon for a total consideration of $810m to support its rare disease portfolio. The deal involves an upfront payment of $340m …See details»
Pfizer Acquires Rare-Drug Company Therachon for $810 Million
May 8, 2019 Pfizer announced it intends to buy Therachon, a rare disease biotech company based in Basel, Switzerland. Under the terms of the deal, Pfizer will pay $340 million upfront …See details»
Therachon Company Profile - Office Locations, Competitors ... - Craft
Therachon Summary. Company Summary. Overview. TherAchon is a biotech company specializing in research and development. It is engaged in the development of a recombinant …See details»
Pfizer Acquires Clinical-Stage Biotech Therachon
May 8, 2019 “Therachon is a great example of the value that can be built from cutting edge European science,” said Therachon Chairman Tom Woiwode, Managing Director at Versant …See details»
Pfizer acquired Therachon. And now what to expect?
With no certainties but with confidence, Luca Santarelli, Therachon CEO said: “With its rare disease expertise and worldwide reach, Pfizer is well positioned to accelerate the development …See details»
Pfizer acquires rare disease biotech Therachon for $340m
Jul 2, 2019 Pfizer has announced it has completed its acquisition of US-based Therachon, a clinical stage biotechnology company focusing on rare diseases; the acquisition was first …See details»
Pfizer acquires Therachon and its dwarfism drug | pharmaphorum
May 8, 2019 There’s also an additional $470 million worth of payments on the table contingent on Therachon achieving certain milestones in the development and commercialisation of TA …See details»
Pfizer to Acquire Therachon for Up to $810M, Expanding Rare …
May 8, 2019 Pfizer has agreed to acquire Therachon Holdings for up to $810 million, the companies said today, in a deal intended to expand the buyer’s rare disease portfolio with a …See details»
Rare disease startup Therachon to absorb GLyPharma and its SBS ...
Oct 9, 2018 Therachon’s previously chief candidate, an FGFR3 ligand trap named TA-46, is being developed to help restore normal bone growth in people with achondroplasia, a form of …See details»
Pfizer agrees on $340M upfront to buy Therachon for dwarfism drug
May 8, 2019 Pfizer is set to pay $340 million (€304 million) upfront to buy Therachon for its treatment for a form of short-limbed dwarfism. The deal commits Pfizer to up to $470 million in …See details»
Pfizer Acquires Clinical-Stage Biotech Therachon
May 8, 2019 Therachon is a clinical-stage global biotechnology company focused on the discovery and development of innovative treatment for severe, rare conditions with significant …See details»
Pfizer Acquires Clinical-Stage Biotech Therachon
May 8, 2019 Expands Pfizer’s rare disease portfolio with potential first-in-class therapy for achondroplasia, a genetic condition and the most common form of short-limb dwarfism NEW …See details»
Pfizer Completes Acquisition of Therachon - Business Wire
Jul 1, 2019 Pfizer Completes Acquisition of Therachon Early clinical development program for achondroplasia augments Pfizer’s Rare Disease portfolio July 01, 2019 10:00 AM Eastern …See details»
Therachon - Contacts, Employees, Board Members, Advisors
Organization. Therachon . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Highlights. Employee Profiles 3. Number of Board Member and Advisor …See details»